Menu Search
Equities

SkinBioTherapeutics PLC

5KW:DEU

SkinBioTherapeutics PLC

Actions
  • Price (EUR)0.172
  • Today's Change-0.005 / -2.82%
  • Shares traded0.00
  • 1 Year change-16.50%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SkinBioTherapeutics plc is a United Kingdom-based life science company focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company is targeting a number of skin healthcare sectors, which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. Its platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. It targets five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. Its first product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis.

  • Revenue in GBP (TTM)161.65k
  • Net income in GBP-2.88m
  • Incorporated2015
  • Employees11.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SBTX:LSE since
announced		Transaction
value
Bio-Tech Solutions LtdAnnounced11 Oct 202411 Oct 2024Announced42.40%1.63m
Dermatonics LtdDeal completed25 Jan 202425 Jan 2024Deal completed8.61%3.73m
Data delayed at least 15 minutes, as of Nov 22 2024 10:53 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.